Capstone Investment Advisors LLC Invests $468,000 in Tarsus Pharmaceuticals, Inc. $TARS

Capstone Investment Advisors LLC bought a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 7,429 shares of the company’s stock, valued at approximately $468,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TARS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Tarsus Pharmaceuticals by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,143 shares of the company’s stock valued at $1,137,000 after purchasing an additional 1,217 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Tarsus Pharmaceuticals by 2.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,220 shares of the company’s stock worth $3,659,000 after buying an additional 1,394 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Tarsus Pharmaceuticals by 105.8% in the 1st quarter. Jane Street Group LLC now owns 10,456 shares of the company’s stock valued at $537,000 after buying an additional 190,000 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Tarsus Pharmaceuticals by 402.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 140,610 shares of the company’s stock valued at $5,696,000 after buying an additional 112,637 shares in the last quarter. Finally, Invesco Ltd. grew its position in shares of Tarsus Pharmaceuticals by 12.3% in the 2nd quarter. Invesco Ltd. now owns 928,501 shares of the company’s stock valued at $37,614,000 after buying an additional 101,978 shares during the last quarter. 90.01% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Tarsus Pharmaceuticals news, Director Katherine Goodrich sold 2,954 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $62.08, for a total transaction of $183,384.32. Following the completion of the sale, the director directly owned 2,233 shares of the company’s stock, valued at approximately $138,624.64. This trade represents a 56.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William J. Phd Link sold 12,500 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $62.12, for a total value of $776,500.00. Following the sale, the director directly owned 106,786 shares of the company’s stock, valued at $6,633,546.32. The trade was a 10.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 39,850 shares of company stock valued at $2,452,821 in the last quarter. 9.64% of the stock is currently owned by insiders.

Tarsus Pharmaceuticals Trading Down 0.2%

NASDAQ TARS opened at $71.76 on Friday. The firm’s fifty day moving average is $64.39 and its two-hundred day moving average is $65.34. Tarsus Pharmaceuticals, Inc. has a one year low of $48.20 and a one year high of $85.25. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.17 and a current ratio of 3.20. The firm has a market cap of $3.15 billion, a PE ratio of -65.83 and a beta of 0.53.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%.The business had revenue of $173.91 million for the quarter, compared to analyst estimates of $169.65 million. Analysts expect that Tarsus Pharmaceuticals, Inc. will post -2.06 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on TARS shares. Mizuho cut their price target on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Guggenheim dropped their price objective on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating on the stock in a report on Tuesday, July 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Friday, July 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $88.00 target price on shares of Tarsus Pharmaceuticals in a report on Thursday, July 9th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $90.50.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.